Journal
CELL
Volume 162, Issue 5, Pages 938-939Publisher
CELL PRESS
DOI: 10.1016/j.cell.2015.08.005
Keywords
-
Categories
Funding
- NCI NIH HHS [U54 CA193419] Funding Source: Medline
Ask authors/readers for more resources
DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
